{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T05:50:57Z","timestamp":1791438657100,"version":"4.3.3"},"reference-count":152,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.xphs.2026.104527","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:02:31Z","timestamp":1791388951000},"page":"104527","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immunogenicity of biologics delivered in the subcutaneous space: Delineating the contributing factors"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7019-729X","authenticated-orcid":false,"given":"Vibha","family":"Jawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Tourdot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manjunath","family":"Shivaraju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisa","family":"Joubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0569-2865","authenticated-orcid":false,"given":"Sathy","family":"Balu-Iyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7519-8836","authenticated-orcid":false,"given":"Kari","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masano","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karoline Bechtold","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3640-5966","authenticated-orcid":false,"given":"Jochem","family":"Gokemeijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1999-218X","authenticated-orcid":false,"given":"Sy","family":"Gebrekidan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2878-5263","authenticated-orcid":false,"given":"Alison","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Printz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3960-9713","authenticated-orcid":false,"given":"Manuel","family":"Sanchez-Felix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachin","family":"Mittal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Rosenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4614-076X","authenticated-orcid":false,"given":"Nicole","family":"Buist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xphs.2026.104527_bib0001","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1067\/mai.2001.119409","article-title":"Epinephrine absorption in adults: Intramuscular versus subcutaneous injection","volume":"108","author":"Simons","year":"2001","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.xphs.2026.104527_bib0002","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.1200\/JCO.24.01001","article-title":"Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor\u2013Mutated Non\u2013Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study","volume":"42","author":"Leighl","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xphs.2026.104527_bib0003","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1007\/s11095-017-2229-9","article-title":"Optimizing the Bioavailability of Subcutaneously Administered Biotherapeutics Through Mechanochemical Drivers","volume":"34","author":"Collins","year":"2017","journal-title":"Pharm. Res."},{"key":"10.1016\/j.xphs.2026.104527_bib0004","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1080\/17425247.2021.1981286","article-title":"Safety of recombinant human hyaluronidase PH20 for subcutaneous drug delivery","volume":"18","author":"Knowles","year":"2021","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.xphs.2026.104527_bib0005","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.3389\/fimmu.2020.01301","article-title":"T-Cell Dependent Immunogenicity of Protein Therapeutics Pre-clinical Assessment and Mitigation\u2013Updated Consensus and Review 2020","volume":"11","author":"Jawa","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xphs.2026.104527_bib0006","doi-asserted-by":"crossref","first-page":"698","DOI":"10.3389\/fimmu.2020.00698","article-title":"Applying MAPPs Assays to Assess Drug Immunogenicity","volume":"11","author":"Karle","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xphs.2026.104527_bib0007","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1690101","article-title":"MAPPs assays for non-clinical immunogenicity risk assessment: best practices recommended by the European immunogenicity platform","volume":"16","author":"Karle","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xphs.2026.104527_bib0008","article-title":"T cell assays for non-clinical immunogenicity risk assessment: best practices recommended by the European Immunogenicity Platform","volume":"16","author":"Tourdot","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xphs.2026.104527_bib0009","doi-asserted-by":"crossref","first-page":"25266","DOI":"10.1074\/jbc.M111.330902","article-title":"Highly Aggregated Antibody Therapeutics Can Enhance the in Vitro Innate and Late-stage T-cell Immune Responses","volume":"287","author":"Joubert","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.xphs.2026.104527_bib0010","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.xphs.2016.11.001","article-title":"In Vivo Effect of Innate Immune Response Modulating Impurities on the Skin Milieu Using a Macaque Model: Impact on Product Immunogenicity","volume":"106","author":"Haile","year":"2017","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.xphs.2026.104527_bib0011","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.4155\/bio-2021-0077","article-title":"In vitro immunogenicity prediction: bridging between innate and adaptive immunity","volume":"13","author":"Cohen","year":"2021","journal-title":"Bioanalysis"},{"key":"10.1016\/j.xphs.2026.104527_bib0012","first-page":"1","article-title":"A Mechanistic, Multiscale Mathematical Model of Immunogenicity for Therapeutic Proteins: Part 1\u2014Theoretical Model","volume":"3","author":"Chen","year":"2014","journal-title":"CPT: Pharmacomet. Syst. Pharmacol"},{"key":"10.1016\/j.xphs.2026.104527_bib0013","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2021.1993522","article-title":"Assay format diversity in pre-clinical immunogenicity risk assessment: Toward a possible harmonization of antigenicity assays","volume":"14","author":"Ducret","year":"2022","journal-title":"mAbs"},{"key":"10.1016\/j.xphs.2026.104527_bib0014","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1080\/19420862.2019.1612699","article-title":"Investigation of pre-existing reactivity to biotherapeutics can uncover potential immunogenic epitopes and predict immunogenicity risk","volume":"11","author":"Bivi","year":"2019","journal-title":"mAbs"},{"key":"10.1016\/j.xphs.2026.104527_bib0015","doi-asserted-by":"crossref","first-page":"eabq5068","DOI":"10.1126\/scitranslmed.abq5068","article-title":"A root cause analysis to identify the mechanistic drivers of immunogenicity against the anti-VEGF biotherapeutic brolucizumab","volume":"15","author":"Kearns","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.xphs.2026.104527_bib0016","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1208\/s12248-016-9878-1","article-title":"Pre-existing Antibody: Biotherapeutic Modality-Based Review","volume":"18","author":"Gorovits","year":"2016","journal-title":"AAPS J"},{"key":"10.1016\/j.xphs.2026.104527_bib0017","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3390\/antib14030062","article-title":"Immunogenicity Risk Assessment of Biotherapeutics Using an Ex Vivo B Cell Assay","volume":"14","author":"Budge","year":"2025","journal-title":"Antibodies"},{"key":"10.1016\/j.xphs.2026.104527_bib0018","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1002\/jps.22276","article-title":"Impact of product-related factors on immunogenicity of biotherapeutics","volume":"100","author":"Singh","year":"2011","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.xphs.2026.104527_bib0019","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s12247-019-09423-2","article-title":"Product-Related Factors and Immunogenicity of Biotherapeutics","volume":"15","author":"Krishna","year":"2020","journal-title":"J. Pharm. Innov."},{"key":"10.1016\/j.xphs.2026.104527_bib0020","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1023\/B:PHAM.0000029275.41323.a6","article-title":"Structure-Immunogenicity Relationships of Therapeutic Proteins","volume":"21","author":"Hermeling","year":"2004","journal-title":"Pharm. Res."},{"key":"10.1016\/j.xphs.2026.104527_bib0021","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s40259-020-00465-4","article-title":"Immunogenicity Challenges Associated with Subcutaneous Delivery of Therapeutic Proteins","volume":"35","author":"Jarvi","year":"2021","journal-title":"BioDrugs"},{"key":"10.1016\/j.xphs.2026.104527_bib0022","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1002\/jps.23415","article-title":"Characterization and quantitation of aggregates and particles in interferon-\u03b2 products: Potential links between product quality attributes and immunogenicity","volume":"102","author":"Barnard","year":"2013","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.xphs.2026.104527_bib0023","doi-asserted-by":"crossref","DOI":"10.1017\/S0033583516000172","article-title":"Secondary nucleation of monomers on fibril surface dominates \u03b1-synuclein aggregation and provides autocatalytic amyloid amplification","volume":"50","author":"Gaspar","year":"2017","journal-title":"Q. Rev. Biophys."},{"key":"10.1016\/j.xphs.2026.104527_bib0024","doi-asserted-by":"crossref","first-page":"7065","DOI":"10.1073\/pnas.1601899113","article-title":"Chemical properties of lipids strongly affect the kinetics of the membrane-induced aggregation of \u03b1-synuclein","volume":"113","author":"Galvagnion","year":"2016","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.xphs.2026.104527_bib0025","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.915412","article-title":"Immunogenicity Risk Assessment of Spontaneously Occurring Therapeutic Monoclonal Antibody Aggregates","volume":"13","author":"Swanson","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xphs.2026.104527_bib0026","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/ni.2039","article-title":"Immunological mechanisms of vaccination","volume":"12","author":"Pulendran","year":"2011","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.xphs.2026.104527_bib0027","doi-asserted-by":"crossref","first-page":"740","DOI":"10.4161\/mabs.22066","article-title":"Immunogenicity of different stressed IgG monoclonal antibody formulations in immune tolerant transgenic mice","volume":"4","author":"Filipe","year":"2012","journal-title":"mAbs"},{"key":"10.1016\/j.xphs.2026.104527_bib0028","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1016\/j.xphs.2019.01.015","article-title":"Impact of Precipitation of Antibody Therapeutics After Subcutaneous Injection on Pharmacokinetics and Immunogenicity","volume":"108","author":"Kinderman","year":"2019","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.xphs.2026.104527_bib0029","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s11095-019-2689-1","article-title":"In Vivo Stability of Therapeutic Proteins","volume":"37","author":"Schuster","year":"2020","journal-title":"Pharm. Res."},{"key":"10.1016\/j.xphs.2026.104527_bib0030","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.xphs.2018.01.007","article-title":"Challenges and Opportunities for the Subcutaneous Delivery of Therapeutic Proteins","volume":"107","author":"Turner","year":"2018","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.xphs.2026.104527_bib0031","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.xphs.2020.12.003","article-title":"The Impact of Product and Process Related Critical Quality Attributes on Immunogenicity and Adverse Immunological Effects of Biotherapeutics","volume":"110","author":"Wen","year":"2021","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.xphs.2026.104527_bib0032","first-page":"265","article-title":"Effects of arginine in therapeutic protein formulations: a decade review and perspectives","volume":"6","author":"Ren","year":"2023","journal-title":"Antib. Ther."},{"key":"10.1016\/j.xphs.2026.104527_bib0033","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.xphs.2020.12.016","article-title":"Product-Specific Impact of Viscosity Modulating Formulation Excipients During Ultra-High Concentration Biotherapeutics Drug Product Development","volume":"110","author":"Rodrigues","year":"2021","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.xphs.2026.104527_bib0034","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1023\/A:1012168621337","article-title":"Development and Use of Enzyme-Linked Immunosorbent Assays (ELISA) for the Detection of Protein Aggregates in Interferon-Alpha (IFN-\u03b1) Formulations","volume":"14","author":"Braun","year":"1997","journal-title":"Pharm. Res."},{"key":"10.1016\/j.xphs.2026.104527_bib0035","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.xphs.2019.10.069","article-title":"Comparison of Polysorbate 80 Hydrolysis and Oxidation on the Aggregation of a Monoclonal Antibody","volume":"109","author":"Larson","year":"2020","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.xphs.2026.104527_bib0036","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1208\/s12248-022-00757-3","article-title":"Risk Factors, Hyaluronidase Expression, and Clinical Immunogenicity of Recombinant Human Hyaluronidase PH20, an Enzyme Enabling Subcutaneous Drug Administration","volume":"24","author":"Printz","year":"2022","journal-title":"AAPS J"},{"key":"10.1016\/j.xphs.2026.104527_bib0037","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1021\/cr050247k","article-title":"Hyaluronidases: Their Genomics, Structures, and Mechanisms of Action","volume":"106","author":"Stern","year":"2006","journal-title":"Chem. Rev."},{"key":"10.1016\/j.xphs.2026.104527_bib0038","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s10875-024-01769-8","article-title":"Long-Term Safety of Facilitated Subcutaneous Immunoglobulin 10% Treatment in US Clinical Practice in Patients with Primary Immunodeficiency Diseases: Results from a Post-Authorization Safety Study","volume":"44","author":"Rubinstein","year":"2024","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.xphs.2026.104527_bib0039","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.annonc.2023.05.009","volume":"34","author":"Burotto","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xphs.2026.104527_bib0040","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.xphs.2021.09.030","article-title":"Stress Factors in Protein Drug Product Manufacturing and Their Impact on Product Quality","volume":"111","author":"Das","year":"2022","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.xphs.2026.104527_bib0041","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1208\/s12248-013-9510-6","article-title":"Immunogenicity of Subcutaneously Administered Therapeutic Proteins\u2014a Mechanistic Perspective","volume":"15","author":"Fathallah","year":"2013","journal-title":"AAPS J"},{"key":"10.1016\/j.xphs.2026.104527_bib0042","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1016\/j.xphs.2017.05.030","article-title":"Perspectives on Subcutaneous Route of Administration as an Immunogenicity Risk Factor for Therapeutic Proteins","volume":"106","author":"Hamuro","year":"2017","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.xphs.2026.104527_bib0044","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1093\/annonc\/mdu524","article-title":"Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH study","volume":"26","author":"Jackisch","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xphs.2026.104527_bib0045","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s40425-019-0586-0","article-title":"Immunogenicity of immunomodulatory, antibody-based, oncology therapeutics","volume":"7","author":"Davda","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.xphs.2026.104527_bib0046","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/jcph.818","article-title":"Evaluation of Immunogenicity of Nivolumab Monotherapy and Its Clinical Relevance in Patients With Metastatic Solid Tumors","volume":"57","author":"Agrawal","year":"2017","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.xphs.2026.104527_bib0047","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.annonc.2024.09.002","article-title":"Subcutaneous versus intravenous nivolumab for renal cell carcinoma \u2606","volume":"36","author":"Albiges","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xphs.2026.104527_bib0048","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1208\/s12248-024-00954-2","article-title":"Immunogenicity of Atezolizumab: Influence of Testing Method and Sampling Frequency on Reported Anti-drug Antibody Incidence Rates","volume":"26","author":"Usdin","year":"2024","journal-title":"AAPS J"},{"key":"10.1016\/j.xphs.2026.104527_bib0049","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s40425-019-0663-4","article-title":"Immunogenicity of pembrolizumab in patients with advanced tumors","volume":"7","author":"Vugt","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.xphs.2026.104527_bib0050","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/jcph.2340","article-title":"Immunogenicity of Cemiplimab: Low Incidence of Antidrug Antibodies and Cut-Point Suitability Across Tumor Types","volume":"64","author":"Valentine","year":"2024","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.xphs.2026.104527_bib0052","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.annonc.2025.03.012","article-title":"Subcutaneous versus intravenous pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-small-cell lung cancer: the phase III 3475A-D77 trial","volume":"36","author":"Felip","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xphs.2026.104527_bib0053","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1208\/s12248-025-01069-y","article-title":"Model-Informed Immunogenicity Assessment of Nivolumab as Monotherapy and in Combination with Ipilimumab","volume":"27","author":"Zhao","year":"2025","journal-title":"AAPS J"},{"key":"10.1016\/j.xphs.2026.104527_bib0054","doi-asserted-by":"crossref","first-page":"e272","DOI":"10.1016\/S2352-3026(17)30078-9","article-title":"Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial","volume":"4","author":"Davies","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.xphs.2026.104527_bib0055","doi-asserted-by":"crossref","unstructured":"Jain, C. R. J. B. L. R. G. L. C. M. L. C. D. M. S. P. V. F. G. D. de A. V. S. O. O. A. E. C. L. Abstract CT143: Pembrolizumab bioavailability after subcutaneous administration: analysis from the KEYNOTE-555 Cohort A in metastatic melanoma. in vol. 81 (13_Supplement): CT143 (2021).","DOI":"10.1158\/1538-7445.AM2021-CT143"},{"key":"10.1016\/j.xphs.2026.104527_bib0056","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aag1286","article-title":"Post hoc assessment of the immunogenicity of bioengineered factor VIIa demonstrates the use of preclinical tools","volume":"9","author":"Lamberth","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.xphs.2026.104527_bib0057","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.xphs.2022.01.032","article-title":"Implementing a Clinical Immunogenicity Strategy using Preclinical Risk Assessment Outputs","volume":"111","author":"Jawa","year":"2022","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.xphs.2026.104527_bib0058","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.637963","article-title":"Introduction of Non-natural Amino Acids Into T-Cell Epitopes to Mitigate Peptide-Specific T-Cell Responses","volume":"12","author":"Azam","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xphs.2026.104527_bib0059","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.1182\/blood-2007-01-069245","article-title":"Decreased expression of tumor necrosis factor family receptors involved in humoral immune responses in preterm neonates","volume":"110","author":"Kaur","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.xphs.2026.104527_bib0060","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1182\/blood.V128.22.2085.2085","article-title":"Defining Fundamental B Cell-Subset Dysfunction in Myeloma","volume":"128","author":"Prabhala","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.xphs.2026.104527_bib0061","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/nri3646","article-title":"Mechanisms regulating skin immunity and inflammation","volume":"14","author":"Pasparakis","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.xphs.2026.104527_bib0062","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41577-018-0084-5","article-title":"The immunological anatomy of the skin","volume":"19","author":"Kabashima","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.xphs.2026.104527_bib0063","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.coi.2012.11.007","article-title":"Antigen presentation by Langerhans cells","volume":"25","author":"Igy\u00e1rt\u00f3","year":"2013","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.xphs.2026.104527_bib0064","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.immuni.2008.07.013","article-title":"Functional Specializations of Human Epidermal Langerhans Cells and CD14+ Dermal Dendritic Cells","volume":"29","author":"Klechevsky","year":"2008","journal-title":"Immunity"},{"key":"10.1016\/j.xphs.2026.104527_bib0065","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jdermsci.2014.08.012","article-title":"Human skin dendritic cells in health and disease","volume":"77","author":"Haniffa","year":"2015","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.xphs.2026.104527_bib0066","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nri3683","article-title":"The origins and functions of dendritic cells and macrophages in the skin","volume":"14","author":"Malissen","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.xphs.2026.104527_bib0067","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.immuni.2004.08.007","article-title":"Visualizing the First 50 Hr of the Primary Immune Response to a Soluble Antigen","volume":"21","author":"Catron","year":"2004","journal-title":"Immunity"},{"key":"10.1016\/j.xphs.2026.104527_bib0068","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.2353\/ajpath.2007.070225","article-title":"CXCL12-CXCR4 Engagement Is Required for Migration of Cutaneous Dendritic Cells","volume":"171","author":"Kabashima","year":"2007","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.xphs.2026.104527_bib0069","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/nri1670","article-title":"Dendritic-cell trafficking to lymph nodes through lymphatic vessels","volume":"5","author":"Randolph","year":"2005","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.xphs.2026.104527_bib0070","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1046\/j.1365-2249.2003.02146.x","article-title":"IL-1\u03b2-induced Langerhans\u2019 cell migration and TNF-\u03b1 production in human skin: regulation by lactoferrin","volume":"132","author":"CUMBERBATCH","year":"2003","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.xphs.2026.104527_bib0071","doi-asserted-by":"crossref","first-page":"4361","DOI":"10.4049\/jimmunol.168.9.4361","article-title":"Matrix Metalloproteinases 9 and 2 Are Necessary for the Migration of Langerhans Cells and Dermal Dendritic Cells from Human and Murine Skin","volume":"168","author":"Ratzinger","year":"2002","journal-title":"J. Immunol."},{"key":"10.1016\/j.xphs.2026.104527_bib0072","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120530","article-title":"Understanding the effect of counterpressure buildup during syringe injections","volume":"602","author":"Shahriar","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.xphs.2026.104527_bib0073","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1007\/s12325-019-01101-6","article-title":"Subcutaneous Injection of Drugs: Literature Review of Factors Influencing Pain Sensation at the Injection Site","volume":"36","author":"Usach","year":"2019","journal-title":"Adv. Ther."},{"key":"10.1016\/j.xphs.2026.104527_bib0074","doi-asserted-by":"crossref","DOI":"10.1016\/j.eml.2023.102025","article-title":"Experimental and computational analysis of the injection-induced mechanical changes in the skin microenvironment during subcutaneous injection of biologics","volume":"61","author":"Shen","year":"2023","journal-title":"Extreme Mech. Lett."},{"key":"10.1016\/j.xphs.2026.104527_bib0075","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1039\/D1CB00067E","article-title":"Aggregation of protein therapeutics enhances their immunogenicity: causes and mitigation strategies","volume":"2","author":"Lundahl","year":"2021","journal-title":"RSC Chem. Biol."},{"key":"10.1016\/j.xphs.2026.104527_bib0076","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.xphs.2019.08.005","article-title":"Proteolysis and Oxidation of Therapeutic Proteins After Intradermal or Subcutaneous Administration","volume":"109","author":"Varkhede","year":"2020","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.xphs.2026.104527_bib0077","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/s41577-024-01027-3","article-title":"DAMP sensing and sterile inflammation: intracellular, intercellular and inter-organ pathways","volume":"24","author":"Huang","year":"2024","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.xphs.2026.104527_bib0078","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1007\/s11095-013-1154-9","article-title":"In Vivo Fluorescence Imaging of IgG1 Aggregates After Subcutaneous and Intravenous Injection in Mice","volume":"31","author":"Filipe","year":"2014","journal-title":"Pharm. Res."},{"key":"10.1016\/j.xphs.2026.104527_bib0079","first-page":"576","article-title":"Pharmacokinetics of Monoclonal Antibodies","volume":"6","author":"Ryman","year":"2017","journal-title":"CPT: Pharmacomet. Syst. Pharmacol."},{"key":"10.1016\/j.xphs.2026.104527_bib0080","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1124\/dmd.114.059238","article-title":"Subcutaneous Absorption of Biotherapeutics: Knowns and Unknowns","volume":"42","author":"Richter","year":"2014","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.xphs.2026.104527_bib0081","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1200\/JCO.2021.39.15_suppl.2575","article-title":"CheckMate 8KX: Phase 1\/2 multitumor preliminary analyses of a subcutaneous formulation of nivolumab (\u00b1 rHuPH20)","volume":"39","author":"Lonardi","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xphs.2026.104527_bib0082","doi-asserted-by":"crossref","unstructured":"Kurata, B. H. \u2219 P. C. \u2219 M. L. J. \u2219 L. J. \u2219 S. J. K. \u2219 S. S. \u2219 M. L. \u2219 T. 168TiP KEYNOTE-A86: Phase III, randomized, open-label study of first-line subcutaneous (SC) vs intravenous (IV) pembrolizumab with platinum doublet chemotherapy in metastatic squamous or nonsquamous non-small cell lung cancer (NSCLC). Annals of Oncology 32, S1456.","DOI":"10.1016\/j.annonc.2021.10.187"},{"key":"10.1016\/j.xphs.2026.104527_bib0083","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.xphs.2022.02.001","article-title":"Use of In Vitro Human Skin Models to Assess Potential Immune Activation In Response to Biotherapeutic Attributes and Process-related Impurities","volume":"111","author":"Tokuda","year":"2022","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.xphs.2026.104527_bib0084","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0159328","article-title":"Use of In Vitro Assays to Assess Immunogenicity Risk of Antibody-Based Biotherapeutics","volume":"11","author":"Joubert","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.xphs.2026.104527_bib0085","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ejpb.2018.06.008","article-title":"In vitro models for immunogenicity prediction of therapeutic proteins","volume":"130","author":"Groell","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.xphs.2026.104527_bib0086","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jconrel.2015.07.016","article-title":"A novel in vitro method to model the fate of subcutaneously administered biopharmaceuticals and associated formulation components","volume":"214","author":"Kinnunen","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.xphs.2026.104527_bib0087","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2024.2352887","article-title":"Predicting the clinical subcutaneous absorption rate constant of monoclonal antibodies using only the primary sequence: a machine learning approach","volume":"16","author":"Bei","year":"2024","journal-title":"mAbs"},{"key":"10.1016\/j.xphs.2026.104527_bib0088","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s11095-021-03022-y","article-title":"Machine Learning Attempts for Predicting Human Subcutaneous Bioavailability of Monoclonal Antibodies","volume":"38","author":"Lou","year":"2021","journal-title":"Pharm. Res."},{"key":"10.1016\/j.xphs.2026.104527_bib0089","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1406040","article-title":"Preclinical immunogenicity risk assessment of biotherapeutics using CD4 T cell assays","volume":"15","author":"Walsh","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xphs.2026.104527_bib0090","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/s43856-023-00413-7","article-title":"A mechanistic marker-based screening tool to predict clinical immunogenicity of biologics","volume":"3","author":"Jarvi","year":"2023","journal-title":"Commun. Med."},{"key":"10.1016\/j.xphs.2026.104527_bib0091","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1039\/c0ib00041h","article-title":"Microfluidic platform for chemotaxis in gradients formed by CXCL12 source-sink cells","volume":"2","author":"Torisawa","year":"2010","journal-title":"Integr. Biol."},{"key":"10.1016\/j.xphs.2026.104527_bib0092","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2025.125490","article-title":"Development of an ex vivo human skin model and evaluation of biological responses to subcutaneously injected hyaluronic acid formulations","volume":"674","author":"Gou","year":"2025","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.xphs.2026.104527_bib0093","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1111\/all.16273","article-title":"Multimodal profiling of biostabilized human skin modules reveals a coordinated ecosystem response to injected mRNA-1273 COVID-19 vaccine","volume":"79","author":"Scholaert","year":"2024","journal-title":"Allergy"},{"key":"10.1016\/j.xphs.2026.104527_bib0094","first-page":"299","article-title":"Microphysiological endothelial models to characterize subcutaneous drug absorption","volume":"40","author":"Offeddu","year":"2022","journal-title":"ALTEX"},{"key":"10.1016\/j.xphs.2026.104527_bib0095","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202302903","article-title":"Microfluidic-Based Reconstitution of Functional Lymphatic Microvasculature: Elucidating the Role of Lymphatics in Health and Disease","volume":"11","author":"Serrano","year":"2024","journal-title":"Adv. Sci."},{"key":"10.1016\/j.xphs.2026.104527_bib0096","first-page":"164","article-title":"Engineering human immune organoids for translational immunology","volume":"44","author":"Suhito","year":"2025","journal-title":"Bioact. Mater."},{"key":"10.1016\/j.xphs.2026.104527_bib0097","doi-asserted-by":"crossref","DOI":"10.1016\/j.xjidi.2024.100315","article-title":"Advances in Microengineered Platforms for Skin Research","volume":"5","author":"Teertam","year":"2025","journal-title":"JID Innov"},{"key":"10.1016\/j.xphs.2026.104527_bib0098","doi-asserted-by":"crossref","DOI":"10.1038\/srep37471","article-title":"Skin-on-a-chip model simulating inflammation, edema and drug-based treatment","volume":"6","author":"Wufuer","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.xphs.2026.104527_bib0099","first-page":"164","article-title":"Engineering human immune organoids for translational immunology","volume":"44","author":"Suhito","year":"2025","journal-title":"Bioact. Mater."},{"key":"10.1016\/j.xphs.2026.104527_bib0100","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/nmeth.1591","article-title":"A more efficient method to generate integration-free human iPS cells","volume":"8","author":"Okita","year":"2011","journal-title":"Nat. Methods"},{"key":"10.1016\/j.xphs.2026.104527_bib0101","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.stem.2019.02.005","article-title":"Targeted Disruption of HLA Genes via CRISPR-Cas9 Generates iPSCs with Enhanced Immune Compatibility","volume":"24","author":"Xu","year":"2019","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.xphs.2026.104527_bib0102","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.molmed.2017.02.007","article-title":"Disease Modeling in Stem Cell-Derived 3D Organoid Systems","volume":"23","author":"Dutta","year":"2017","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.xphs.2026.104527_bib0103","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.xphs.2016.02.031","article-title":"Mouse Models for Assessing Protein Immunogenicity: Lessons and Challenges","volume":"105","author":"Jiskoot","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.xphs.2026.104527_bib0104","first-page":"1","article-title":"Potential Applications and Perspectives of Humanized Mouse Models","volume":"10","author":"Ye","year":"2021","journal-title":"Annu. Rev. Anim. Biosci."},{"key":"10.1016\/j.xphs.2026.104527_bib0105","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1038\/s41590-024-01880-3","article-title":"A humanized mouse that mounts mature class-switched, hypermutated and neutralizing antibody responses","volume":"25","author":"Chupp","year":"2024","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.xphs.2026.104527_bib0106","doi-asserted-by":"crossref","first-page":"243","DOI":"10.4161\/mabs.4.2.19387","article-title":"Minipig as a potential translatable model for monoclonal antibody pharmacokinetics after intravenous and subcutaneous administration","volume":"4","author":"Zheng","year":"2012","journal-title":"mAbs"},{"key":"10.1016\/j.xphs.2026.104527_bib0107","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1038\/s41551-022-00921-2","article-title":"A humanized minipig model for the toxicological testing of therapeutic recombinant antibodies","volume":"6","author":"Flisikowska","year":"2022","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.xphs.2026.104527_bib0108","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/s41568-023-00573-7","article-title":"Humanized minipigs to assess drug safety","volume":"23","author":"Flisikowska","year":"2023","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.xphs.2026.104527_bib0109","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3109\/1547691X.2013.796023","article-title":"The minipig as an alternative non-rodent model for immunogenicity testing using the TNF\u03b1 blockers adalimumab and infliximab","volume":"11","author":"Mierlo","year":"2014","journal-title":"J. Immunotoxicol."},{"key":"10.1016\/j.xphs.2026.104527_bib0110","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.613810","article-title":"G\u00f6ttingen Minipigs as a Model to Evaluate Longevity, Functionality, and Memory of Immune Response Induced by Pertussis Vaccines","volume":"12","author":"Vaure","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xphs.2026.104527_bib0111","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1080\/17460441.2020.1811671","article-title":"What are the practical, ethical, and pathobiological considerations in the use of minipigs as an animal model in drug discovery for acute radiation syndrome and delayed effects of acute radiation exposure?","volume":"16","author":"Kenchegowda","year":"2021","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.xphs.2026.104527_bib0112","unstructured":"Advancing New Alternative Methodologie at FDA. https:\/\/www.fda.gov\/media\/144891\/download."},{"key":"10.1016\/j.xphs.2026.104527_bib0113","unstructured":"Regulatory science strategy |European Medicines Agency (EMA). https:\/\/www.ema.europa.eu\/en\/documents\/regulatory-procedural-guideline\/ema-regulatory-science-2025-strategic-reflection_en.pdf."},{"key":"10.1016\/j.xphs.2026.104527_bib0114","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/cpt.3150","article-title":"Subcutaneous Administration of Monoclonal Antibodies: Pharmacology, Delivery, Immunogenicity, and Learnings From Applications to Clinical Development","volume":"115","author":"Davis","year":"2024","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.xphs.2026.104527_bib0115","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1002\/art.30463","article-title":"Subcutaneous abatacept versus intravenous abatacept: A phase IIIb noninferiority study in patients with an inadequate response to methotrexate","volume":"63","author":"Genovese","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.xphs.2026.104527_bib0116","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1002\/art.40466","article-title":"Subcutaneous Abatacept in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis","volume":"70","author":"Brunner","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.xphs.2026.104527_bib0117","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1093\/rheumatology\/kez030","article-title":"Immunogenicity of biologic agents in juvenile idiopathic arthritis: a systematic review and meta-analysis","volume":"58","author":"Doeleman","year":"2019","journal-title":"Rheumatology"},{"key":"10.1016\/j.xphs.2026.104527_bib0118","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0140-6736(08)60998-8","article-title":"Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial","volume":"372","author":"Ruperto","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.xphs.2026.104527_bib0119","doi-asserted-by":"crossref","DOI":"10.1111\/1755-5922.12309","volume":"36","author":"Gumbiner","year":"2018","journal-title":"Cardiovasc. Ther."},{"key":"10.1016\/j.xphs.2026.104527_bib0120","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1056\/NEJMoa1614062","article-title":"Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab","volume":"376","author":"Ridker","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xphs.2026.104527_bib0121","first-page":"2013","article-title":"Population PK\/PD modeling of low-density lipoprotein cholesterol response in hypercholesterolemic participants following administration of bococizumab, a potent anti-PCSK9 monoclonal antibody","volume":"12","author":"Wang","year":"2023","journal-title":"CPT: Pharmacomet. Syst. Pharmacol."},{"key":"10.1016\/j.xphs.2026.104527_bib0122","doi-asserted-by":"crossref","first-page":"7116","DOI":"10.1182\/blood-2022-163192","article-title":"Soluble Factors Correlated with High-Grade Cytokine Release Syndrome (CRS): A Comparison of Subcutaneous (SC) Versus Intravenous (IV) Delivery of Alnuctamab (ALNUC; BMS-986349; CC-93269) in Patients (pts) with Relapsed\/Refractory Multiple Myeloma (RRMM)","volume":"140","author":"Boss","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.xphs.2026.104527_bib0123","doi-asserted-by":"crossref","DOI":"10.1097\/01.HS9.0000970204.77796.ce","article-title":"P825: SOLUBLE FACTORS CORRELATED WITH CYTOKINE RELEASE SYNDROME (CRS) WITH IV VS SUBCUTANEOUS (SC) ALNUCTAMAB (ALNUC; BMS-986349; CC-93269) IN PATIENTS WITH RELAPSED\/REFRACTORY MULTIPLE MYELOMA (RRMM)","volume":"7","author":"Boss","year":"2023","journal-title":"HemaSphere"},{"key":"10.1016\/j.xphs.2026.104527_bib0124","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1158\/1078-0432.CCR-24-2247","article-title":"Clinical Pharmacology of Cytokine Release Syndrome with T-Cell\u2013Engaging Bispecific Antibodies: Current Insights and Drug Development Strategies","volume":"31","author":"Radtke","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xphs.2026.104527_bib0125","unstructured":"TECENTRIQ HYBREZATM. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761347s000lbl.pdf."},{"key":"10.1016\/j.xphs.2026.104527_bib0126","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1208\/s12248-024-00930-w","article-title":"Anti-Drug Antibody Incidence Comparison of Therapeutic Proteins Administered Via Subcutaneous vs. Intravenous Route","volume":"26","author":"Felderman","year":"2024","journal-title":"AAPS J"},{"key":"10.1016\/j.xphs.2026.104527_bib0127","doi-asserted-by":"crossref","first-page":"e370","DOI":"10.1016\/S2352-3026(20)30070-3","article-title":"Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial","volume":"7","author":"Mateos","year":"2020","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.xphs.2026.104527_bib0128","doi-asserted-by":"crossref","first-page":"6574","DOI":"10.1200\/JCO.2023.41.16_suppl.6574","article-title":"Incidence of infusion related reactions of daratumumab-hyaluronidase-fihj: Pre-post intervention study of premedication omission","volume":"41","author":"Padmaraju","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xphs.2026.104527_bib0129","author":"FASPRO\u00ae"},{"key":"10.1016\/j.xphs.2026.104527_bib0130","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.xphs.2026.104527_bib0131","author":"Biotech"},{"key":"10.1016\/j.xphs.2026.104527_bib0132","unstructured":"Biotech, J. & Inc. Simponi Aria (Golimumab). Highlights of Prescribing Information. (2009)."},{"key":"10.1016\/j.xphs.2026.104527_bib0133","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1053\/j.gastro.2021.02.068","article-title":"Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease","volume":"160","author":"Schreiber","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.xphs.2026.104527_bib0134","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","article-title":"Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma","volume":"371","author":"Bel","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xphs.2026.104527_bib0135","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S2213-2600(17)30125-X","article-title":"Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial","volume":"5","author":"Chupp","year":"2017","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.xphs.2026.104527_bib0136","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xphs.2026.104527_bib0137","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00258-25","article-title":"VH3810109 (N6LS) broadly neutralizing antibody safety, pharmacokinetics, and anti-drug antibody incidence in adults without HIV: phase 1 SPAN study results","volume":"69","author":"Leone","year":"2025","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.xphs.2026.104527_bib0140","author":"OCREVUS"},{"key":"10.1016\/j.xphs.2026.104527_bib0141","article-title":"Omontys (Peginesatide). Highlights of Prescribing Information","year":"2012","journal-title":"Omontys (peginesatide). Highlights of prescribing information"},{"key":"10.1016\/j.xphs.2026.104527_bib0143","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S1470-2045(20)30536-2","article-title":"Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study","volume":"22","author":"Tan","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.xphs.2026.104527_bib0144","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/cpdd.887","article-title":"Safety, Tolerability, and Pharmacokinetics of PF-06823859, an Anti\u2013Interferon \u03b2 Monoclonal Antibody: A Randomized, Phase I, Single- and Multiple-Ascending-Dose Study","volume":"10","author":"Neelakantan","year":"2021","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"10.1016\/j.xphs.2026.104527_bib0146","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1001\/jamaoncol.2019.0836","article-title":"Assessment of Subcutaneous vs Intravenous Administration of Anti\u2013PD-1 Antibody PF-06801591 in Patients With Advanced Solid Tumors","volume":"5","author":"Johnson","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.xphs.2026.104527_bib0147","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2147\/JPR.S135257","article-title":"Safety and efficacy of subcutaneous tanezumab in patients with knee or hip osteoarthritis","volume":"11","author":"Birbara","year":"2018","journal-title":"J. Pain Res."},{"key":"10.1016\/j.xphs.2026.104527_bib0148","author":"(tocilizumab)"},{"key":"10.1016\/j.xphs.2026.104527_bib0149","author":"(trastuzumab)"},{"key":"10.1016\/j.xphs.2026.104527_bib0150","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1053\/j.gastro.2019.08.027","article-title":"Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.xphs.2026.104527_bib0151","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.3324\/haematol.2017.173583","article-title":"Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study","volume":"102","author":"Lugtenburg","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.xphs.2026.104527_bib0152","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/S1470-2045(12)70329-7","article-title":"Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I\u2013III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial","volume":"13","author":"Ismael","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.xphs.2026.104527_bib0153","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.1200\/JCO.24.01001","article-title":"Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor\u2013Mutated Non\u2013Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study","volume":"42","author":"Leighl","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xphs.2026.104527_bib0154","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/acr.22110","article-title":"Phase III Study of the Efficacy and Safety of Subcutaneous Versus Intravenous Tocilizumab Monotherapy in Patients With Rheumatoid Arthritis","volume":"66","author":"Ogata","year":"2014","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.xphs.2026.104527_bib0155","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1136\/annrheumdis-2013-203523","volume":"73","author":"Burmester","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.xphs.2026.104527_bib0156","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1002\/art.30463","article-title":"Subcutaneous abatacept versus intravenous abatacept: A phase IIIb noninferiority study in patients with an inadequate response to methotrexate","volume":"63","author":"Genovese","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.xphs.2026.104527_bib0157","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000213909","article-title":"Subcutaneous Ocrelizumab in Patients With Multiple Sclerosis","volume":"105","author":"Newsome","year":"2025","journal-title":"Neurology"},{"key":"10.1016\/j.xphs.2026.104527_bib0158","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurot.2024.e00378","article-title":"Subcutaneous efgartigimod PH20 in generalized myasthenia gravis: A phase 3 randomized noninferiority study (ADAPT-SC) and interim analyses of a long-term open-label extension study (ADAPT-SC+)","volume":"21","author":"Howard","year":"2024","journal-title":"Neurotherapeutics"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354926003771?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354926003771?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T05:06:33Z","timestamp":1791435993000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354926003771"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":152,"alternative-id":["S0022354926003771"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2026.104527","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity of biologics delivered in the subcutaneous space: Delineating the contributing factors","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2026.104527","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104527"}}